The US FTC files an amicus brief challenging the abuse of the FDA’s "orange book" listing procedures which allow companies to automatically block the entry of generic drugs for a period of 30 months (Jazz Pharmaceuticals / Avadel CNS Pharmaceuticals)

FTC Amicus Brief Challenges Abuse of FDA “Orange Book” Listing Procedures to Block Drug Competition* The Federal Trade Commission filed an amicus brief with the U.S. District Court for the District of Delaware in the case of Jazz Pharmaceuticals v. Avadel CNS Pharmaceuticals. The Brief highlights the significant harm to consumers when a brand company improperly lists a patent on a distribution system in the Food and Drug

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC files an amicus brief challenging the abuse of the FDA’s "orange book" listing procedures which allow companies to automatically block the entry of generic drugs for a period of 30 months (Jazz Pharmaceuticals / Avadel CNS Pharmaceuticals), 10 November 2022, e-Competitions November 2022 - II, Art. N° 109496

Visites 91

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues